Skip to main content
. Author manuscript; available in PMC: 2015 Nov 11.
Published in final edited form as: Bioconjug Chem. 2014 Nov 24;25(12):2197–2204. doi: 10.1021/bc500415x

Figure 3.

Figure 3

Serial PET imaging of EGFR expression. (A) Serial coronal PET images at 0.5, 2, 4, and 6 h p.i. of (I) 44Sc-CHX-A″-DTPA-Cetuximab-Fab in U87MG tumor bearing mice (targeted), (II) 44Sc-CHX-A″-DTPA-denatured-Cetuximab-Fab in U87MG tumor bearing mice (non-targeted), (III)44Sc-CHX-A″-DTPA-Cetuximab-Fab after treatment with a 2 mg blocking dose of Cetuximab before injection in U87MG tumor bearing mice, and (IV) 44Sc-CHX-A″-DTPA-Cetuximab-Fab in Caco-2 tumor bearing mice (negative control). (B) Representative PET/CT images of U87MG tumor bearing mouse at 4 h p.i. of 44Sc-CHX-A″-DTPA-Cetuximab-Fab. Arrowheads indicate tumors.